Document Detail


Pulsed high-intensity-focused US and tissue plasminogen activator (TPA) versus TPA alone for thrombolysis of occluded bypass graft in swine.
MedLine Citation:
PMID:  22609287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Prosthetic arteriovenous or arterial-arterial bypass grafts can thrombose and be resistant to revascularization. A thrombosed bypass graft model was created to evaluate the potential therapeutic enhancement and safety profile of pulsed high-intensity-focused ultrasound (pHIFU) on pharmaceutical thrombolysis.
MATERIALS AND METHODS: In swine, a right carotid-carotid expanded polytetrafluoroethylene bypass graft was surgically constructed, containing a 40% stenosis at its distal end to induce graft thrombosis. The revascularization procedure was performed 7 days after surgery. After model development and dose response experiments (n = 11), two cohorts were studied: pHIFU with tissue plasminogen activator (TPA; n = 4) and sham pHIFU with TPA (n = 3). The experiments were identical in both groups except no energy was delivered in the sham pHIFU group. Serial angiograms were obtained in all cases. The area of graft opacified by contrast medium on angiograms was quantified with digital image processing software. A blinded reviewer calculated the change in the graft area opacified by contrast medium and expressed it as a percentage, representing percentage of thrombolysis.
RESULTS: Combining pHIFU with 0.5 mg of TPA resulted in a 52% ± 4% increase in thrombolysis on angiograms obtained at 30 minutes, compared with a 9% ± 14% increase with sham pHIFU and 0.5 mg TPA (P = .003). Histopathologic examination demonstrated no differences between the groups.
CONCLUSIONS: Thrombolysis of occluded bypass grafts was significantly increased when combining pHIFU and TPA versus sham pHIFU and TPA. These results suggest that application of pHIFU may augment thrombolysis with a reduced time and dose.
Authors:
Nadine Abi-Jaoudeh; William F Pritchard; Hayet Amalou; Marius Linguraru; Oscar A Chiesa; Joshua D Adams; Carmen Gacchina; Robert Wesley; Subha Maruvada; Briana McDowell; Victor Frenkel; John W Karanian; Bradford J Wood
Related Documents :
8784407 - Gut is not a source of cytokines in a porcine model of endotoxicosis.
6606187 - Arterialization of the portal vein for control of variceal bleeding. clinical and angio...
17004537 - Cardiac perforation and tamponade: a potentially fatal complication during transjugular...
8654157 - Pancreatic arteriovenous malformation with duodenal ulcer. demonstration by color doppl...
20948197 - High-grade internal carotid artery stenosis and chronic brain damage: a volumetric magn...
20667207 - Gdc embolisation of cavernous internal carotid artery aneurysms with parent artery pres...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2012-05-19
Journal Detail:
Title:  Journal of vascular and interventional radiology : JVIR     Volume:  23     ISSN:  1535-7732     ISO Abbreviation:  J Vasc Interv Radiol     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-22     Completed Date:  2012-11-16     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  9203369     Medline TA:  J Vasc Interv Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  953-961.e2     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD 20892, USA. naj@mail.nih.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Combined Modality Therapy
High-Intensity Focused Ultrasound Ablation
Swine
Thrombolytic Therapy
Thrombosis / etiology*,  therapy*
Tissue Plasminogen Activator
Treatment Outcome
Vascular Grafting / adverse effects*
Grant Support
ID/Acronym/Agency:
1Z01CL046011-01/CL/CLC NIH HHS; Z01 CL040011-01/CL/CLC NIH HHS; Z99 CL999999/CL/CLC NIH HHS; ZIA CL040011-04/CL/CLC NIH HHS; ZIA CL040012-04/CL/CLC NIH HHS
Chemical
Reg. No./Substance:
EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Midterm follow-up of transjugular intrahepatic portosystemic shunts using polytetrafluoroethylene en...
Next Document:  Aortic Branch Artery Pseudoaneurysms Accompanying Aortic Dissection. Part III: Natural History.